CellaVision AB (publ) (CEVI.ST)
SEK 222.0
(2.07%)
SEK 222.0
(2.07%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 295.99 Million SEK | 5.69% |
| 2022 | 280.05 Million SEK | 21.99% |
| 2021 | 229.57 Million SEK | 13.22% |
| 2020 | 202.76 Million SEK | -3.52% |
| 2019 | 210.15 Million SEK | 31.96% |
| 2018 | 159.25 Million SEK | 20.35% |
| 2017 | 132.32 Million SEK | 15.3% |
| 2016 | 114.76 Million SEK | 5.52% |
| 2015 | 108.76 Million SEK | 6.33% |
| 2014 | 102.28 Million SEK | 18.01% |
| 2013 | 86.68 Million SEK | -2.99% |
| 2012 | 89.35 Million SEK | 6.87% |
| 2011 | 83.61 Million SEK | 13.59% |
| 2010 | 73.6 Million SEK | 19.28% |
| 2009 | 61.71 Million SEK | 23.13% |
| 2008 | 50.11 Million SEK | 19.02% |
| 2007 | 42.11 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 75.43 Million SEK | 2.99% |
| 2024 Q1 | 73.24 Million SEK | -0.17% |
| 2024 Q3 | 82.89 Million SEK | 9.88% |
| 2023 Q4 | 73.36 Million SEK | -6.12% |
| 2023 Q2 | 72.64 Million SEK | 1.13% |
| 2023 FY | 295.98 Million SEK | 5.69% |
| 2023 Q1 | 71.82 Million SEK | 14.76% |
| 2023 Q3 | 78.15 Million SEK | 7.59% |
| 2022 Q4 | 62.58 Million SEK | -21.24% |
| 2022 FY | 280.05 Million SEK | 21.99% |
| 2022 Q1 | 65.8 Million SEK | 4.93% |
| 2022 Q2 | 72.19 Million SEK | 9.71% |
| 2022 Q3 | 79.45 Million SEK | 10.06% |
| 2021 Q2 | 54.88 Million SEK | 0.57% |
| 2021 Q4 | 62.71 Million SEK | 9.27% |
| 2021 Q1 | 54.57 Million SEK | 1.13% |
| 2021 FY | 229.57 Million SEK | 13.22% |
| 2021 Q3 | 57.39 Million SEK | 4.58% |
| 2020 Q1 | 58.79 Million SEK | -13.58% |
| 2020 Q4 | 53.96 Million SEK | 33.52% |
| 2020 FY | 202.76 Million SEK | -3.52% |
| 2020 Q3 | 40.41 Million SEK | -18.5% |
| 2020 Q2 | 49.59 Million SEK | -15.66% |
| 2019 Q2 | 49.15 Million SEK | 16.82% |
| 2019 Q3 | 50.88 Million SEK | 3.52% |
| 2019 Q1 | 42.08 Million SEK | -8.78% |
| 2019 FY | 210.15 Million SEK | 31.96% |
| 2019 Q4 | 68.03 Million SEK | 33.7% |
| 2018 Q1 | 34.53 Million SEK | 2.4% |
| 2018 FY | 159.25 Million SEK | 20.35% |
| 2018 Q4 | 46.13 Million SEK | 12.02% |
| 2018 Q3 | 41.18 Million SEK | 10.09% |
| 2018 Q2 | 37.4 Million SEK | 8.32% |
| 2017 Q4 | 33.72 Million SEK | 2.46% |
| 2017 Q1 | 33.66 Million SEK | 8.15% |
| 2017 Q2 | 32.02 Million SEK | -4.88% |
| 2017 Q3 | 32.91 Million SEK | 2.8% |
| 2017 FY | 132.32 Million SEK | 15.3% |
| 2016 Q4 | 31.12 Million SEK | 9.55% |
| 2016 FY | 114.76 Million SEK | 5.52% |
| 2016 Q2 | 28.25 Million SEK | 4.72% |
| 2016 Q3 | 28.41 Million SEK | 0.56% |
| 2016 Q1 | 26.97 Million SEK | -10.08% |
| 2015 Q4 | 30 Million SEK | 22.27% |
| 2015 Q3 | 24.53 Million SEK | -13.63% |
| 2015 Q2 | 28.41 Million SEK | 10.06% |
| 2015 FY | 108.76 Million SEK | 6.33% |
| 2015 Q1 | 25.81 Million SEK | -23.27% |
| 2014 Q1 | 20.48 Million SEK | -12.8% |
| 2014 FY | 102.28 Million SEK | 18.01% |
| 2014 Q4 | 33.64 Million SEK | 48.25% |
| 2014 Q3 | 22.69 Million SEK | -10.91% |
| 2014 Q2 | 25.47 Million SEK | 24.36% |
| 2013 Q2 | 23.75 Million SEK | 4.82% |
| 2013 Q3 | 16.77 Million SEK | -29.39% |
| 2013 Q4 | 23.48 Million SEK | 40.03% |
| 2013 FY | 86.68 Million SEK | -2.99% |
| 2013 Q1 | 22.66 Million SEK | -8.92% |
| 2012 Q4 | 24.88 Million SEK | 33.71% |
| 2012 Q1 | 21.71 Million SEK | -14.17% |
| 2012 Q2 | 24.15 Million SEK | 11.24% |
| 2012 Q3 | 18.6 Million SEK | -22.95% |
| 2012 FY | 89.35 Million SEK | 6.87% |
| 2011 Q3 | 18.9 Million SEK | -10.3% |
| 2011 FY | 83.61 Million SEK | 13.59% |
| 2011 Q4 | 25.29 Million SEK | 33.8% |
| 2011 Q1 | 18.33 Million SEK | -7.36% |
| 2011 Q2 | 21.07 Million SEK | 14.96% |
| 2010 Q2 | 19.67 Million SEK | 6.59% |
| 2010 Q3 | 15.68 Million SEK | -20.31% |
| 2010 Q1 | 18.46 Million SEK | 150.79% |
| 2010 FY | 73.6 Million SEK | 19.28% |
| 2010 Q4 | 19.78 Million SEK | 26.2% |
| 2009 Q3 | 17.25 Million SEK | 8.81% |
| 2009 Q1 | 13.25 Million SEK | 72.84% |
| 2009 Q4 | 7.36 Million SEK | -57.33% |
| 2009 Q2 | 15.85 Million SEK | 19.63% |
| 2009 FY | 61.71 Million SEK | 23.13% |
| 2008 FY | 50.11 Million SEK | 19.02% |
| 2008 Q2 | 12.41 Million SEK | 0.0% |
| 2008 Q3 | 15.32 Million SEK | 23.42% |
| 2008 Q4 | 7.66 Million SEK | -49.96% |
| 2007 FY | 42.11 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -257.26% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 51.62% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 51.62% |
| Arcoma AB | 53.25 Million SEK | -455.829% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -5856.732% |
| BICO Group AB (publ) | 2.84 Billion SEK | 89.609% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | -40.65% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -329.407% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -22508.757% |
| C-Rad AB (publ) | 3.8 Million SEK | -7689.211% |
| Duearity AB (publ) | 21.58 Million SEK | -1271.276% |
| Dignitana AB (publ) | 74.73 Million SEK | -296.047% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -10862.593% |
| Getinge AB (publ) | 10.75 Billion SEK | 97.249% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -1523.771% |
| Iconovo AB (publ) | 63.35 Million SEK | -367.197% |
| Integrum AB (publ) | 90.57 Million SEK | -226.803% |
| Luxbright AB (publ) | 23.09 Million SEK | -1181.868% |
| Mentice AB (publ) | 237.06 Million SEK | -24.859% |
| OssDsign AB (publ) | 175.6 Million SEK | -68.558% |
| Paxman AB (publ) | 133.8 Million SEK | -121.218% |
| Promimic AB (publ) | 48.55 Million SEK | -509.635% |
| Qlife Holding AB (publ) | 162.38 Million SEK | -82.277% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -322.988% |
| ScandiDos AB (publ) | 61.03 Million SEK | -384.927% |
| Sectra AB (publ) | 39.06 Million SEK | -657.725% |
| Sedana Medical AB (publ) | 174.52 Million SEK | -69.595% |
| Senzime AB (publ) | 141.51 Million SEK | -109.155% |
| SpectraCure AB (publ) | 12.12 Million SEK | -2340.551% |
| Stille AB | 87.21 Million SEK | -239.364% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 94.683% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 32.871% |